28 Advanced Solid Tumors Clinical Trials in Rochester, MI (2026)

Q: How do I join a clinical trial in Rochester?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Rochester research site will contact you.

Recruiting Advanced Solid Tumors Studies in Rochester

NCT02457962Recruiting

Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study

To collect and analyze specimens that will correlate with clinical outcomes such as acute and late toxicities, quality of life, local control, and survival of patients treated with photon/proton thera...

Rochester, MI15,000 participantsMayo Clinic

View Study Details

NCT06179160Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies....

Rochester, MI710 participantsIncyte Corporation

View Study Details

NCT06051695Recruiting

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell l...

Rochester, MI474 participantsA2 Biotherapeutics Inc.

View Study Details

NCT04855656Recruiting

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced sol...

Rochester, MI464 participantsDebiopharm International SA

View Study Details

NCT05932862Recruiting

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of ...

Rochester, MI429 participantsExelixis

View Study Details

NCT05824975Recruiting

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembro...

Rochester, MI358 participantsGI Innovation, Inc.

View Study Details

NCT06973564Recruiting

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

This study is to evaluate the safety and tolerability of JAB-23E73 in adult participants with advanced solid tumors...

Rochester, MI294 participantsJacobio Pharmaceuticals Co., Ltd.

View Study Details

NCT05954312Recruiting

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab....

Rochester, MI290 participantsVividion Therapeutics, Inc.

View Study Details

NCT06963281Recruiting

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020....

Rochester, MI285 participantsInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

View Study Details

NCT06657222Recruiting

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To ...

Rochester, MI250 participantsTubulis GmbH

View Study Details

NCT06682793Recruiting

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head a...

Rochester, MI240 participantsA2 Biotherapeutics Inc.

View Study Details

NCT06259552Recruiting

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an...

Rochester, MI232 participantsSparX Biotech(Jiangsu) Co., Ltd.

View Study Details

NCT07109726Recruiting

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors ha...

Rochester, MI205 participantsTerremoto Biosciences Inc.

View Study Details

NCT04981119Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible p...

Rochester, MI200 participantsA2 Biotherapeutics Inc.

View Study Details

NCT06810544Recruiting

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an op...

Rochester, MI191 participantsTango Therapeutics, Inc.

View Study Details

NCT07415031Recruiting

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in c...

Rochester, MI170 participantsMirati Therapeutics Inc.

View Study Details

NCT06625593Recruiting

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agent...

Rochester, MI168 participantsBeOne Medicines

View Study Details

NCT05873686Recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected...

Rochester, MI140 participantsNuvectis Pharma, Inc.

View Study Details

NCT05394103Recruiting

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monother...

Rochester, MI130 participantsQurient Co., Ltd.

View Study Details

NCT06395519Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor acti...

Rochester, MI120 participants858 Therapeutics, Inc.

View Study Details

NCT05103683Recruiting

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer...

Rochester, MI90 participantsTORL Biotherapeutics, LLC

View Study Details

NCT06994806Recruiting

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are: * ...

Rochester, MI84 participantsKumquat Biosciences Inc.

View Study Details

NCT07393529Recruiting

A Pilot Randomized Controlled Trial of a Social Network Intervention

This is a pilot randomized controlled trial to assess the feasibility, acceptability, appropriateness, and structure of the SONATA intervention. In addition, it will assess the preliminary efficacy of...

Rochester, MI70 participantsUniversity of Rochester

View Study Details

NCT06005740Recruiting

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid...

Rochester, MI70 participantsTORL Biotherapeutics, LLC

View Study Details

NCT07659158Recruiting

Virtual Group Resilient Living Program For Patients Living With Advanced Cancer

This study is a prospective, minimal risk, non-randomized, single-arm study to determine feasibility and assess effectiveness of a Virtual Group Resilient Living Program (RLP) on anxiety, stress, qual...

Rochester, MI42 participantsMayo Clinic

View Study Details

NCT07192432Recruiting

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers....

Rochester, MI27 participantsVironexis Biotherapeutics Inc.

View Study Details

NCT07224464Recruiting

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.

This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sara...

Rochester, MI12 participantsNew Phase Ltd.

View Study Details

NCT07054944Recruiting

Tumor-Lymph Node Mapping

The purpose of this study is to assess the feasibility and safety of ICG-guided intraoperative lymphography for detecting sentinel lymph nodes (SLN) in pediatric patients with solid tumors who require...

Rochester, MI10 participantsUniversity of Rochester

View Study Details

About Advanced Solid Tumors Clinical Trials in Rochester

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 28 advanced solid tumors clinical trials recruiting participants in Rochester, MI. These studies are seeking a combined 20,755 participants. Research is being sponsored by Mayo Clinic, Incyte Corporation, A2 Biotherapeutics Inc. and 20 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Rochester — FAQ

Are there advanced solid tumors clinical trials in Rochester?

Yes, there are 28 advanced solid tumors clinical trials currently recruiting in Rochester, MI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Rochester?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Rochester research site will contact you about next steps.

Are clinical trials in Rochester free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Rochester studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 28 active trials in Rochester are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 13, 2026 from ClinicalTrials.gov